Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357630 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00357630 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 52 participants.
The verdict
NCT00357630, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with metastatic cancer of unknown primary.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357630
The ClinicalTrials.gov registry entry for NCT00357630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00357630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357630 about?
NCT00357630 is a clinical study titled "Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with metastatic cancer of unk...
What is the current status of trial NCT00357630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2006-06.
What interventions are being tested in trial NCT00357630?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00357630?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.